Endocrine Abstracts

Introduction: There has been an increase in the use of new drugs called immune checkpoint inhibitors (ICPI) used in advanced tumors. Clinical trials have also reported an increased risk of developing immune-related adverse events (IRAEs). Endocrine IRAEs may be particularly relevant.Material and Methods: This is a retrospective study. Patients treated with ICPI were obtained from Medical Oncology departament of the General University Hospital of Albacete...